摘要：
Capsaicin is the main active ingredient of chili peppers and the most pungent alkaloid. It is reported that capsaicin has many pharmacological effects such as analgesia, anticancer, anti-inflammatory, antibacterial, and anti-obesity. However, the application of capsaicin is limited by its adverse side effects, such as stomach irritation, stomach cramps, and burning sensation. In recent years, many capsaicin derivatives have been synthesized and their biological activities have been evaluated. Some capsaicin derivatives have shown promising activities in cells and animal models. Herein, we described the synthesis and biological activity of capsaicin and its derivatives. It is hoped that the insights obtained in this perspective will facilitate the synthesis of a second generation of capsaicin analogs with improved biological activities.
摘要：
<jats:sec>
<jats:title>Abstract:</jats:title>
<jats:p>Aurones are structural isomers of flavones and flavonols with the basic C6–C3–C6 skeleton
arranged as (Z)-2-benzylidenebenzofuran-3(2H)-one, which contain an exocyclic carbon-carbon
double bond bridging the benzofuranone and phenyl rings. In aurone, a chalcone-like group is closed
into a 5-membered ring instead of the 6-membered ring more typical of flavonoids, which forms the
core for a family of derivatives that are known collectively as aurones. As a kind of flavonoids, aurones
are widely distributed in many plants which provide yellow color to some popular ornamental
flowers. For a long time aurones had not got enough attention, while in recent years, finally this
chemical is coming into researchers' view. As the secondary metabolite in the family of flavonoids,
aurones displayed various biological activities, including antioxidant, antiparasitic, antitumor, antiviral,
antibacterial, anti-inflammatory, anti-SARS-CoV-2 and neuropharmacological activities. Therefore,
aurones have attracted the attention of more and more chemists and pharmaceutical chemists,
who realized that it is possible to get lead compounds with better activities via structural modifications
of aurones. In some research works, aurone and its derivatives have exhibited good activity,
e.g., Xie discovered the heterocyclic variant of the (Z)-2-benzylidene-6-hydroxybenzofuran-3(2H)-
one scaffold that possessed low nanomolar in vitro potency in cell proliferation assays using various
cancer cell lines, in vivo potency in prostate cancer PC-3 xenograft and zebrafish models, and absence
of appreciable toxicity, which proved that aurones are valuable compounds worthy of further
study. Herein, the biological activities of aurone derivatives are reviewed, which covers the literature
since 2000, in which the strategies to develop bioactive aurone derivatives and the structureactivity
relationship are highlighted.</jats:p>
</jats:sec>
摘要：
BACKGROUND: Apigenin, a naturally occurring compound with a flavone core structure, is known for its diverse bioactivities, including anti-inflammation, anti-toxicant, anti-cancer and so on. There has been significant interest in the medicinal chemistry community. To address these challenges, researchers have developed various derivatives of apigenin to address challenges such as poor water-solubility and low intestinal absorption, aiming to enhance the pharmacological activities and pharmacokinetic properties of this compound. OBJECTIVE: In recent years, there has been a proliferation of apigenin derivatives with enhanced bioactivity. However, there is a lack of comprehensive reviews on the function-based modification of these derivatives. In this paper, we provide an overview of the apigenin derivatives with varying bioactivities and explored their structure activity relationships. And the functions of different groups of apigenin derivatives were also analyzed. CONCLUSION: This review summarized the current achievements that could provide some clues for further study of apigenin-based drugs.
期刊：
European Journal of Medicinal Chemistry,2024年263:115956 ISSN：0223-5234
通讯作者：
Mi, Pengbing;Yuan, Zhonghua;Zheng, X;Lin, YW
作者机构：
[Tan, Yan; Yuan, Zhonghua; Mi, Pengbing; Jiang, Jinhuan; Chen, Limei; Luo, Jianxiong; Zheng, Xing; Ye, Shiying; Lin, Yuqing; Zheng, X] Univ South China, Dept Pharm, Hengyang Med Sch, Hengyang 421001, Hunan, Peoples R China.;[Lang, Jia-Jia; Lin, Ying-Wu] Univ South China, Sch Chem & Chem Engn, Hengyang 421001, Hunan, Peoples R China.;[Lang, Jia-Jia; Lin, Ying-Wu; Mi, Pengbing] Univ South China, Key Lab Prot Struct & Funct Univ Hunan Prov, Hengyang 421001, Hunan, Peoples R China.;[Zheng, Xing] Hunan Vocat Coll Sci & Technol, Dept Pharm, Changsha 410004, Hunan, Peoples R China.;[Lv, You] Shaanxi Univ Sci & Technol, Coll Bioresources Chem & Mat Engn, Xian 710021, Shaanxi, Peoples R China.
通讯机构：
[Yuan, ZH; Mi, PB; Lin, YW ; Zheng, X ] U;Univ South China, Dept Pharm, Hengyang Med Sch, Hengyang 421001, Hunan, Peoples R China.;Univ South China, Sch Chem & Chem Engn, Hengyang 421001, Hunan, Peoples R China.
关键词：
Human monoamine oxidase B inhibitor;Thiochromone;Thiochromone S,S-dioxide
摘要：
Developing new scaffolds for highly potent and selective inhibitors of human Monoamine Oxidase B (hMAO-B) is a crucial objective in enhancing the efficacy and safety in the clinical treatment of neurodegenerative diseases. In this study, we have identified a series of C-3 isoxazole-substituted thiochromone S,S-dioxide derivatives that exhibit strong inhibitory activity against hMAO-B. The strategy of oxidizing thiochromone to thiochromone S,S-dioxide solves the key defect of extreme insolubility observed for thiochromone analogues. In addition, the sulfone group contributes extra hydrogen(H)-bonding interactions with Tyr435, which significantly increases the activity of thiochromone S,S-dioxide derivatives against hMAO-B. Furthermore, the presence of isoxazole group provides potential H-bonding interaction and electrostatic interaction with the residue of Tyr326, while the rigid aryl ring introduces a potential steric conflict with Phe208 of hMAO-A to improve both potency and selectivity. In our investigations, several compounds (9c, 10c, 10e, 10g, 10l and 10m) demonstrate remarkable single-digit nanomolar potency. These compounds exhibit favorable cytotoxicity profiles in both differentiated SH-SY5Y and HVSMC cells, without apparent cardiotoxic effects. Moreover, compounds 10e and 10h do not lead to an increase in ROS levels in differentiated SH-SY5Y cells, further demonstrating their potential as safe and effective hMAO-B inhibitors. These findings indicate that the C-3 isoxazole substituted thiochromone S,S-dioxide analogues are potential leading compounds for the development of selective inhibitors with high potency.
摘要：
The development of highly selective Janus Kinase 1 (JAK1) inhibitors is crucial for improving efficacy and minimizing adverse effects in the clinical treatment of autoimmune diseases. In a prior study, we designed a series of C-5 4-pyrazol substituted pyrrolopyridine derivatives that demonstrated significant potency against JAK1, with a 10∼20-fold selectivity over Janus Kinase 2 (JAK2). Building on this foundation, we adopted orthogonal strategy by modifying the C-5 position with 3-pyrazol/4-pyrazol/3-pyrrol groups and tail with substituted benzyl groups on the pyrrolopyridine head to enhance both potency and selectivity. In this endeavor, we have identified several compounds that exhibit excellent potency and selectivity for JAK1. Notably, compounds 12b and 12e, which combined 4-pyrazol group at C-5 site and meta-substituted benzyl tails, displayed IC(50) value with 2.4/2.2nM and high 352-/253-fold selectivity for JAK1 over JAK2 in enzyme assays. Additionally, both compounds showed good JAK1-selective in Ba/F3-TEL-JAK1/2 cell-based assays. These findings mark a substantial improvement, as these compounds are 10-fold more potent and over 10-fold more selective than the best compound identified in our previous study. The noteworthy potency and selectivity properties of compounds 12b and 12e suggest their potential utility in furthering the development of drugs for autoimmune diseases.
摘要：
<jats:title>Abstract</jats:title><jats:p>Curcumin, derived from the popular spice turmeric, is a pharmacologically active polyphenol. Curcumin's therapeutic activity has been extensively studied in recent decades, with reports implicating curcumin in many biological activities, particularly, its significant anticancer activity. However, its potential as an oral administration product is hampered by poor bioavailability, which is associated with a variety of factors, including low water solubility, poor intestinal permeability, instability, and degradation at alkaline pH. To improve its bioavailability, modifying β‐diketone curcumin with heterocycles, such as pyrazole, isoxazole and triazole is a powerful strategy. Derivatives are synthesized while maintaining the basic skeleton of curcumin. The β‐diketone cyclized curcumin derivatives are regulators of multiple molecular targets, which play vital roles in a variety of cellular pathways. In some literatures, structurally modified curcumin derivatives have been compared with curcumin, and the former has enhanced biological activity, improved water solubility and stability. Therefore, the scope of this review is to report the most recently synthesized heterocyclic derivatives and to classify them according to their chemical structures. Several of the most important and effective compounds are reviewed by introducing different active groups into the β‐diketone position to achieve better therapeutic efficacy and bioavailability.</jats:p>
摘要：
<jats:sec>
<jats:title>Abstract:</jats:title>
<jats:p>As a beneficial natural flavonoid, genistein has demonstrated a wide range of biological functions
via regulating a number of targets and signaling pathways, such as anti-cancer, antioxidant, antibacterial, antiinflammatory, antifungal, antiviral, iron chelation, anti-obesity, anti-diabetes, and anti-hypertension. PubMed/Medline and Web of Science were searched using appropriate keywords until the end of December 2023.
Despite its many potential benefits, genistein’s clinical application is limited by low hydrophilicity, poor solubility, and suboptimal bioavailability due to its structure. These challenges can be addressed through the conversion of genistein into glycosides. Glycosylation of active small molecules may enhance their solubility,
stability, and biological activity. In recent years, extensive research has been conducted on the synthesis, properties, and anticancer activity of glycoconjugates. Previous reviews were devoted to discussing the biological
activities of genistin, with a little summary of the biosynthesis and the structure-activity relationship for their
anticancer activity of genistein glycoside derivatives. Therefore, we summarized recent advances in the biosynthesis of genistein glycosylation and discussed the antitumor activities of genistein glycoside derivatives in a
structure-activity relationship, which may provide important information for further development of genistein
derivatives.</jats:p>
</jats:sec>
摘要：
<jats:sec>
<jats:title>Background:</jats:title>
<jats:p>Genistein has been limited in clinical application due to its low bioavailability, extremely poor liposolubility, and fast glycosylation rate, though it possesses anti-breast cancer activity. Therefore, the discovery of novel genistein derivatives is an urgency.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Objective:</jats:title>
<jats:p>To enhance the anti-breast cancer activity of genistein, a series of novel fluorinated genistein derivatives were synthesized.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Method:</jats:title>
<jats:p>Their in vitro antitumor activity was investigated by the MTT assay against three cancer cell lines, via., MDA-MB-231, MCF-7 and MDA-MB-435, respectively.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results:</jats:title>
<jats:p>Analogs 1d, 2b, 3b showed remarkable anticancer activities comparing to tamoxifen, a clinical anti-breast cancer drug on the market.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion:</jats:title>
<jats:p>The activities against breast cancer of genistein were enhanced by introducing 7-alkoxyl group and fluorine atom into the B-ring. Therefore, these compounds may be potential candidates for treating breast cancer.</jats:p>
</jats:sec>
摘要：
Ursolic acid (UA) is a widely distributed triterpenoid in nature. Due to its easy availability and multiple pharmacological activities, ursolic acid has attracted much attention in the field of medicine and pharmacology. To overcome the disadvantages of bioavailability and poor water solubility during the ursolic acid application, we focused on the synthetic and medicinal properties of UA derivatives modified at C-3 and C-28 sites. This review presents the synthesis of UA derivatives with modification at C-3 and C-28 sites and their pharmacological activity, which may provide some important information for further research and development of UA-based drugs.
作者机构：
[Chen, Hong-Fei; Yang, Ze-Hua; Gao, Cong-Xi; Wu, Ting-Juan; Peng, Ya-Ling; Liu, Qian-Wen; Tang, Cai-Hong; Hu, Yue; Liu, Mei-Ling; Zheng, Xing] Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hunan Prov Key Lab Tumor Microenvironm Respons Dr, Grp Lead Compound,Dept Pharm,Hengyang Med Sch, Hengyang 421001, Peoples R China.;[Gao, Cong-Xi] Kunming Med Univ, Sch Pharm, Kunming 650500, Yunnan, Peoples R China.;[Gao, Cong-Xi] Kunming Med Univ, Yunnan Key Lab Nat Med Pharmacol, Kunming 650500, Yunnan, Peoples R China.
通讯机构：
[Ze-Hua Yang; Xing Zheng] G;Group of Lead Compound, Department of Pharmacy, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang Medicinal School, University of South China, Hengyang421001, China<&wdkj&>Group of Lead Compound, Department of Pharmacy, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang Medicinal School, University of South China, Hengyang421001, China
关键词：
Oleanolic acid derivatives;A ring modification;anticancer activity;C-28 site modification;mechanism of action
摘要：
Oleanolic acid (OA) is a five-ring triterpenoid compound, which is widely present in plants. Due to a wide range of pharmacological activities, oleanolic acid has attracted more and more attention. However, oleanolic acid is insoluble in water and has low bioavailability, which limits its clinical application. In this review, we focus on summarizing the anti-cancer activity and mechanism of the A ring or C-28 carboxyl modified derivatives of OA since 2015, to determine the strength of its anti-cancer effectiveness and evaluate whether it could be used as a clinical anti-cancer drug.
摘要：
Ursolic acid (UA) is a pentacyclic triterpenoid with diverse biological activities, especially in the fields of cardiovascular and diabetes treatment. However, its application is hindered by low bioavailability and poor solubility in water. Consequently, reseacher have focused on designing UA derivatives to address these issues. This paper provides an overview of the development of UA derivatives and their recent advancements as regents for combating cardiovascular diseases and diabetes. Abstract Ursolic acid (UA) is a pentacyclic triterpenoid, which exhibits many biological activities, particularly in anti‐cardiovascular and anti‐diabetes. The further application of UA is greatly limited due to its low bioavailability and poor water solubility. Up to date, various UA derivatives have been designed to overcome these shortcomings. In this paper, the authors reviewed the development of UA derivatives as the anti‐diabetes anti‐cardiovascular reagents.
作者机构：
[Tang, Caihong; Jiang, Zhong-Xing; Yao, Xu; Zheng, Xing] Univ South China, Inst Pharm & Pharmacol, Hengyang Med Sch, Hengyang 421001, Hunan, Peoples R China.;[Zhang, Jianxin; Tang, Feng; Shi, Wei; Zeng, Yue; Tang, Caihong; Huang, Wei] Chinese Acad Sci, Shanghai Inst Mat Med, CAS Ctr Excellence Mol Cell Sci, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China.;[Shi, Wei; Huang, Wei] Hangzhou Inst Adv Study, Sch Pharmaceut Sci & Technol, Hangzhou 310024, Peoples R China.;[Huang, Wei] Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China.;[Huang, Wei] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
通讯机构：
[Xu Yao; Zhong-Xing Jiang] I;[Wei Shi; Wei Huang] C;CAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zuchongzhi Road, Pudong, Shanghai 201203, China<&wdkj&>School of Pharmaceutical Science and Technology, Hangzhou Institute of Advanced Study, Hangzhou 310024, China<&wdkj&>School of Chinese Materia Medica, Nanjing University of Chinese Medicine, No. 138 Xianlin Road, Nanjing 210023, China<&wdkj&>University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China<&wdkj&>Shanghai GlycanLink Biotech. Co. Ltd., Minhang, Shanghai 201203, China<&wdkj&>Institute of Pharmacy and Pharmacology, Hengyang Medicinal School, University of South China, Hengyang, Hunan 421001, China<&wdkj&>CAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zuchongzhi Road, Pudong, Shanghai 201203, China<&wdkj&>School of Pharmaceutical Science and Technology, Hangzhou Institute of Advanced Study, Hangzhou 310024, China
摘要：
The drug-to-antibody ratio (DAR) value and dual-drug combination greatly influence the therapeutic index of antibody–drug conjugates (ADCs). The reported approaches usually require multifunctional branched linkers, a combination of complicated technologies, or protein–protein ligation, which may incorporate multihydrophobic fragments or result in low coupling efficiency. Herein, we developed a facile and efficient one-pot method to assemble dual-site-specific ADCs with defined DARs at both the N-glycosylation site and K248 site, either with the same payloads or with two types of payloads. The constructed dual-site ADCs showed acceptable homogeneity, excellent buffer stability, and enhanced in vitro and in vivo efficiency.
关键词：
Breast cancer;Lead compounds;Multidrug resistance
摘要：
Chemotherapy is the mainstay in the treatment of breast cancer. However, many drugs that are commonly used in clinical practice have a high incidence of side effects and multidrug resistance (MDR), which is mainly caused by overexpression of drug transporters and related enzymes in breast cancer cells. In recent years, researchers have been working hard to find newer and safer drugs to overcome MDR in breast cancer. In this review, we provide the molecule mechanism of MDR in breast cancer, categorize potential lead compounds that inhibit single or multiple drug transporter proteins, as well as related enzymes. Additionally, we have summarized the structure-activity relationship (SAR) based on potential breast cancer MDR modulators with lower side effects. The development of novel approaches to suppress MDR is also addressed. These lead compounds hold great promise for exploring effective chemotherapy agents to overcome MDR, providing opportunities for curing breast cancer in the future.
摘要：
<jats:sec>
<jats:title>Background:</jats:title>
<jats:p>Curcumin is a polyphenol compound extracted from plant turmeric with high
pharmacological activities. The clinical application of curcumin is limited due to the shortcomings of
poor water solubility, instability, and low bioavailability.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Objective:</jats:title>
<jats:p>Modifying the 4', 4''-bit of curcumin is an effective strategy to improve the pharmacological
activity of curcumin.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion:</jats:title>
<jats:p>In this review, we focused on the strategy of synthesis, medicinal properties, and structurefunction
relationship of 4', 4''-bit modified curcumin derivatives.</jats:p>
</jats:sec>
期刊：
JOURNAL OF MEDICINAL CHEMISTRY,2023年66(10):6725-6742 ISSN：0022-2623
通讯作者：
Mi, Pengbing;Zheng, Xing;Lin, YW
作者机构：
[Lang, Jia-Jia; Mi, Pengbing; Lin, Ying-Wu; Zheng, Xing; Zheng, X] Univ South China, Hengyang Med Coll, Sch Chem & Chem Engn, Hengyang 421001, Peoples R China.;[Tan, Yan; Mi, Pengbing; Lin, Ying-Wu; Chen, Limei; Zheng, Xing; Chen, Hongfei; Zheng, X] Univ South China, Hengyang Med Sch, Dept Pharm, Hengyang 421001, Hunan, Peoples R China.;[Lang, Jia-Jia; Mi, Pengbing; Lin, Ying-Wu] Univ South China, Key Lab Prot Struct & Funct Univ Hunan Prov, Hengyang 421001, Peoples R China.;[Wang, Xuechuan; Lv, You] Univ Sci & Technol, Coll Bioresources Chem & Mat Engn, Xian 710021, Shaanxi, Peoples R China.;[Lv, You] Xian Amazinggene Co Ltd, Xian 710026, Shaanxi, Peoples R China.
通讯机构：
[Mi, PB; Lin, YW ; Zheng, X] U;Univ South China, Hengyang Med Sch, Dept Pharm, Hengyang 421001, Hunan, Peoples R China.;Univ South China, Hengyang Med Coll, Sch Chem & Chem Engn, Hengyang 421001, Peoples R China.;Univ South China, Key Lab Prot Struct & Funct Univ Hunan Prov, Hengyang 421001, Peoples R China.
摘要：
Developing selective inhibitors for Janus kinase 1 (JAK1) is a significant focus for improving the efficacy and alleviating the adverse effects in treating immune-inflammatory diseases. Herein, we report the discovery of a series of C-5 pyrazole-modified pyrrolopyrimidine derivatives as JAK1-selective inhibitors. The potential hydrogen bond between the pyrazole group and E966 in JAK1 is the key point that enhances JAK1 selectivity. These compounds exhibit 10- to 20-fold JAK1 selectivity over JAK2 in enzyme assays. Compound 12b also exhibits excellent JAK1 selectivity in Ba/F3-TEL-JAK cellular assays. Metabolism studies and the results of the hair growth model in mice indicate that compound 12b may be a viable lead compound for the development of highly JAK1-selective inhibitors for immune and inflammatory diseases.
通讯机构：
[Zheng, X.] G;[Jiang, Z.-X.] H;Group of Lead Compound, Department of Pharmacy, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang 421001, China
关键词：
(19)F magnetic resonance imaging;Cell tracking;Fluorescence imaging;Nanoemulsions;Paramagnetic effect
摘要：
Fluorine-19 magnetic resonance imaging ((19)F MRI) has been a technology of choice for in vivo cell tracking, in which perfluorocarbons (PFCs) nanoemulsions are the most used (19)F MRI agents. However, the peculiar physicochemical properties of PFCs may lead to poor cell uptake and misleading cell tracking results. Herein, we employed partially fluorinated aromatic agents to formulate paramagnetic nanoemulsions as novel (19)F MRI-fluorescence (FL) dual imaging agents for cell tracking. With the intramolecular π-π interaction, low density and fluorine content, the partially fluorinated agents enable considerable solubilities of functional agents and short relaxation times, which facilitates convenient preparation of stable, biocompatible, and multifunctional nanoemulsions with high (19)F MRI sensitivity. Replacing PFCs in (19)F MRI nanoemulsions with readily available partially fluorinated aromatic agents may address many issues associated with PFCs and provide a novel strategy for high-performance (19)F MRI agents of broad biomedical applications.
通讯机构：
[Hongfei Chen; Xing Zheng] D;Department of Pharmacy, Hengyang Medical School, University of South China, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang, China<&wdkj&>Department of Pharmacy, Hengyang Medical School, University of South China, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang, China
作者机构：
[Yang, Meifang; Zheng, Xing] Univ South China, Dept Pharm, Grp Lead Compound, Hengyang 421001, Hunan, Peoples R China.;[Yang, Meifang; Tao, Houchao] Shanghai Univ Tradit Chinese Med, Innovat Res Inst Tradit Chinese Med, Shanghai Frontiers Sci Ctr TCM Chem Biol, Shanghai 201203, Peoples R China.;[Zhao, Fei; Luo, Weiling; Wang, Huixia; Zhang, Wei; Xue, Dongxiang; Wu, Yiran; Zhao, Suwen] ShanghaiTech Univ, iHuman Inst, Shanghai 201210, Peoples R China.;[Luo, Weiling] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China.;[Luo, Weiling] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
通讯机构：
[Prof. Fei Zhao] i;[Prof. Xing Zheng] G;[Prof. Houchao Tao] S;Group of Lead Compound, Department of Pharmacy, University of South China, Hengyang, Hunan, 421001 P. R. China<&wdkj&>iHuman Institute, ShanghaiTech University, Shanghai, 201210 P. R. China<&wdkj&>Shanghai Frontiers Science Center of TCM Chemical Biology, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203 P. R. China
